Impax, AstraZeneca sign licensing deal for Zomig
As per the agreement, Impax will even have non-exclusive rights to develop new products containing zolmitriptan and to exclusively commercialize these products in the US in connection with
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).